These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 14663006)

  • 1. Adenosine A2A receptor modulation of motor systems for symptomatic therapy in Parkinson's disease.
    Standaert DG
    Neurology; 2003 Dec; 61(11 Suppl 6):S30-1. PubMed ID: 14663006
    [No Abstract]   [Full Text] [Related]  

  • 2. Can adenosine A
    Kanda T; Jenner P
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S21-S27. PubMed ID: 33349576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications.
    Morelli M; Di Paolo T; Wardas J; Calon F; Xiao D; Schwarzschild MA
    Prog Neurobiol; 2007 Dec; 83(5):293-309. PubMed ID: 17826884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenosine A(2A) receptors in nonlocomotor features of Parkinson's disease: introduction.
    Ongini E
    Neurology; 2003 Dec; 61(11 Suppl 6):S72-3. PubMed ID: 14663015
    [No Abstract]   [Full Text] [Related]  

  • 5. Role of adenosine A
    Pinna A; Serra M; Morelli M; Simola N
    J Neural Transm (Vienna); 2018 Aug; 125(8):1273-1286. PubMed ID: 29396609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
    Kase H; Aoyama S; Ichimura M; Ikeda K; Ishii A; Kanda T; Koga K; Koike N; Kurokawa M; Kuwana Y; Mori A; Nakamura J; Nonaka H; Ochi M; Saki M; Shimada J; Shindou T; Shiozaki S; Suzuki F; Takeda M; Yanagawa K; Richardson PJ; Jenner P; Bedard P; Borrelli E; Hauser RA; Chase TN;
    Neurology; 2003 Dec; 61(11 Suppl 6):S97-100. PubMed ID: 14663020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
    Bezard E; Brotchie JM; Gross CE
    Nat Rev Neurosci; 2001 Aug; 2(8):577-88. PubMed ID: 11484001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An approach to the continuous dopaminergic stimulation in Parkinson's disease.
    Schwartz M; Sabetay S
    Isr Med Assoc J; 2012 Mar; 14(3):175-9. PubMed ID: 22675859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological interactions between adenosine A
    Pinna A; Serra M; Marongiu J; Morelli M
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S37-S44. PubMed ID: 33349579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenosine A2A antagonists in Parkinson's disease: what's next?
    Hickey P; Stacy M
    Curr Neurol Neurosci Rep; 2012 Aug; 12(4):376-85. PubMed ID: 22585137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How do adenosine A
    Mori A
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S13-S20. PubMed ID: 33349575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
    Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
    Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should levodopa be used anymore?
    Zegers de Beyl D
    Acta Neurol Belg; 2002 Dec; 102(4):163-6. PubMed ID: 12534242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease.
    Ramlackhansingh AF; Bose SK; Ahmed I; Turkheimer FE; Pavese N; Brooks DJ
    Neurology; 2011 May; 76(21):1811-6. PubMed ID: 21606452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zonisamide ameliorates levodopa-induced dyskinesia and reduces expression of striatal genes in Parkinson model rats.
    Oki M; Kaneko S; Morise S; Takenouchi N; Hashizume T; Tsuge A; Nakamura M; Wate R; Kusaka H
    Neurosci Res; 2017 Sep; 122():45-50. PubMed ID: 28577977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiology of the basal ganglia in Parkinson's disease.
    Obeso JA; Rodríguez-Oroz MC; Rodríguez M; Lanciego JL; Artieda J; Gonzalo N; Olanow CW
    Trends Neurosci; 2000 Oct; 23(10 Suppl):S8-19. PubMed ID: 11052215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.
    Chen JF; Fredduzzi S; Bastia E; Yu L; Moratalla R; Ongini E; Schwarzschild MA
    Neurology; 2003 Dec; 61(11 Suppl 6):S74-81. PubMed ID: 14663016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When and how should treatment be started in Parkinson disease?
    Lang AE
    Neurology; 2009 Feb; 72(7 Suppl):S39-43. PubMed ID: 19221313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The use of piribedil in early and late stages of Parkinson's disease].
    Fedorova NV; Kulua TK; Gubanova ЕN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(10):96-98. PubMed ID: 26525631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.